These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 39115589)

  • 21. Value of repeat radical transurethral resection for selected patients with muscle-invasive bladder cancer.
    Li Z; Li Y; Lu Q; Chen J
    ANZ J Surg; 2018 Oct; 88(10):1033-1036. PubMed ID: 29974604
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Prospective study of effectiveness. Reoperation (re-TUR) in superficial bladder carcinoma].
    Vögeli TA; Grimm MO; Simon X; Ackermann R
    Urologe A; 2002 Sep; 41(5):470-4. PubMed ID: 12426865
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Upstaging after Transurethral Resection of the Bladder for Non-Muscle-Invasive Cancer of the Bladder: Who Is at Highest Risk?
    Volz Y; Trappmann R; Ebner B; Eismann L; Enzinger B; Hermans J; Pyrgidis N; Stief C; Schulz GB
    Urol Int; 2024; 108(1):42-48. PubMed ID: 37944501
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictive factors of the absence of residual disease at repeated transurethral resection of the bladder. Is there a possibility to avoid it in well-selected patients?
    Soria F; D'Andrea D; Moschini M; Giordano A; Mazzoli S; Pizzuto G; Hurle R; Colombo R; Briganti A; Altieri V; Shariat SF; Gontero P
    Urol Oncol; 2020 Mar; 38(3):77.e1-77.e7. PubMed ID: 31526650
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of immediate radical cystectomy in the treatment of patients with residual T1 bladder cancer on restaging transurethral resection.
    Sternberg IA; Keren Paz GE; Chen LY; Herr HW; Dalbagni G
    BJU Int; 2013 Jul; 112(1):54-9. PubMed ID: 23146082
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of time to second transurethral resection on oncological outcomes of patients with high-grade T1 bladder cancer treated with intravesical Bacillus Calmette-Guerin.
    Calò B; Falagario U; Sanguedolce F; Veccia A; Chirico M; Carvalho-Diaz E; Mota P; Lima E; Autorino R; Carrieri G; Cormio L
    World J Urol; 2020 Dec; 38(12):3161-3167. PubMed ID: 32062805
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade/Grade 3 bladder cancer treated with bacille Calmette-Guérin.
    Gontero P; Sylvester R; Pisano F; Joniau S; Oderda M; Serretta V; Larré S; Di Stasi S; Van Rhijn B; Witjes AJ; Grotenhuis AJ; Colombo R; Briganti A; Babjuk M; Soukup V; Malmström PU; Irani J; Malats N; Baniel J; Mano R; Cai T; Cha EK; Ardelt P; Vakarakis J; Bartoletti R; Dalbagni G; Shariat SF; Xylinas E; Karnes RJ; Palou J
    BJU Int; 2016 Jul; 118(1):44-52. PubMed ID: 26469362
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Urinary fibronectin as a predictor of a residual tumour load after transurethral resection of bladder transitional cell carcinoma.
    Li LY; Yang M; Zhang HB; Su XK; Xu WF; Chen Y; Shen ZJ; Gao X
    BJU Int; 2008 Aug; 102(5):566-71. PubMed ID: 18410436
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A new tool for distinguishing muscle invasive and non-muscle invasive bladder cancer: the initial application of flexible ultrasound bronchoscope in bladder tumor staging.
    Xu C; Zhang Z; Wang H; Song Q; Wei R; Yu Y; Li J; Sun Y
    PLoS One; 2014; 9(4):e92385. PubMed ID: 24704988
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Repeat transurethral resection for non-muscle-invasive bladder cancer: a contemporary series.
    Gendy R; Delprado W; Brenner P; Brooks A; Coombes G; Cozzi P; Nash P; Patel MI
    BJU Int; 2016 Apr; 117 Suppl 4():54-9. PubMed ID: 26486968
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical outcomes of second transurethral resection in non-muscle invasive high-grade bladder cancer: a retrospective, multi-institutional, collaborative study.
    Kamiya N; Suzuki H; Suyama T; Kobayashi M; Fukasawa S; Sekita N; Mikami K; Nihei N; Naya Y; Ichikawa T
    Int J Clin Oncol; 2017 Apr; 22(2):353-358. PubMed ID: 27744487
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The impact of restaging transurethral resection on recurrence and progression free survival in patients with T1 high grade bladder cancer].
    Brun A; Koutlidis N; Thibault T; Escoffier A; Bardet F; Cormier L
    Prog Urol; 2023 Mar; 33(3):125-134. PubMed ID: 36604247
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Progression to T1 High Grade (T1HG) from a Lower Stage/Grade is Associated with Poorer Survival Outcomes than Initial Diagnosis with T1HG Bladder Cancer.
    Kim JK; Jeong CW; Kwak C; Kim HH; Ku JH
    Ann Surg Oncol; 2017 Aug; 24(8):2413-2419. PubMed ID: 28560602
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Obesity is associated with worse outcomes in patients with T1 high grade urothelial carcinoma of the bladder.
    Kluth LA; Xylinas E; Crivelli JJ; Passoni N; Comploj E; Pycha A; Chrystal J; Sun M; Karakiewicz PI; Gontero P; Lotan Y; Chun FK; Fisch M; Scherr DS; Shariat SF
    J Urol; 2013 Aug; 190(2):480-6. PubMed ID: 23376707
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic benefit of second-look transurethral resection of bladder tumors for newly diagnosed T1 bladder cancer: a single-center experience.
    Tseng WH; Liu CL; Huang SK; Liao AC; Kuo JR; Hun SH; Chen CH; Su CC; Wang JC; Lee KH; Shen KH; Li CF
    Int Urol Nephrol; 2019 Aug; 51(8):1335-1342. PubMed ID: 31129781
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Second resection in patients with Ta-T1 bladder tumors].
    Rodríguez-Rubio Cortadellas FI; Garrido Insua S; Rivas Aguayo D; Hens Pérez A; Bachiller Burgos J; Beltrán Aguilar V; Varo Solís C; Sánchez Bernal C; Juárez Soto A; González Moreno D
    Actas Urol Esp; 2001 Sep; 25(8):553-8. PubMed ID: 11692797
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A re-staging transurethral resection predicts early progression of superficial bladder cancer.
    Herr HW; Donat SM
    BJU Int; 2006 Jun; 97(6):1194-8. PubMed ID: 16566813
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Invasive, high grade transitional cell carcinoma of the bladder treated with transurethral resection. A survival analysis focusing on TUR as monotherapy.
    Roosen JU; Geertsen U; Jahn H; Weinreich J; Nissen HM
    Scand J Urol Nephrol; 1997 Feb; 31(1):39-42. PubMed ID: 9060082
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk factors for positive findings in patients with high-grade T1 bladder cancer treated with transurethral resection of bladder tumour (TUR) and bacille Calmette-Guérin therapy and the decision for a repeat TUR.
    Orsola A; Cecchini L; Raventós CX; Trilla E; Planas J; Landolfi S; de Torres I; Morote J
    BJU Int; 2010 Jan; 105(2):202-7. PubMed ID: 19558557
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prediction of pathological response following neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: the PRE-PREVENCYS trial.
    Hinsenveld FJ; Noordman BJ; Boormans JL; Voortman J; van Leenders GJLH; van der Pas SL; van Beek SC; Oprea-Lager DE; Vis AN
    BMC Cancer; 2021 Oct; 21(1):1161. PubMed ID: 34715822
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.